Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs.
Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied after a study showed the weight-loss and diabetes drugs reduced the risk of developing Alzheimer's.
Investment firm Bain Capital is in talks to acquire Mitsubishi Chemical Group's pharmaceutical business in a potential multibillion-dollar deal, a transaction that could accelerate the Japanese chemical giant's efforts to focus on key businesses.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
January 21, 2025 17:25 ET (22:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.